Juntunen, P.; Heiska, H.; Olkkola, S.; Myllyniemi, A. L.; Hänninen, M. L. (Finland)
Veterinary Microbiology (2010)
We assessed antimicrobial resistance in C. coli isolates before, during and after tylosin treatment of weaned pigs with proliferative enteropathy at a large pig producing farm. Approximately 3000 weaned pigs were simultaneously treated with tylosin phosphate (Tylan Premix1 20 mg/g) at a Finnish pig farm. Tylosin was administered in feed (140 g in 1000 kg of dry food which is equivalent to a body weight dose of 3– 6 mg/kg/day according to the drug label) from March 2007 to March 2008 to treat proliferative enteropathy caused by L. intracellularis. Faecal samples were collected from 28 sows and 29 piglets not treated with tylosin (controls) in the farrowing unit and from 68 weaned pigs treated with tylosin for 4 days to 8 weeks in the weaning unit. 15 samples were collected from previously tylosin-treated weaned pigs living in the same facility as the treated pigs 3–5 weeks after the cessation of tylosin treatment (posttreatment group). Breakpoints for antimicrobial resistance were defined according to the epidemiological cut-off values provided by the European Committee on Antimicrobial Susceptibility Testing (EUCAST, 2009).
Individual faecal samples were taken from the rectum with Probact transport swabs
AST Method: Broth Microdilution
Reference explicitly reports AST breakpoints: True
Reference reports using a MIC table: True
Is Excluded: False
Country | Sub-Region | Sub-Region Detail |
---|---|---|
Finland | None | None |
ID | Note | Resolution |
---|
Title | Host | Host | Production Stage | Description | ROs |
---|---|---|---|---|---|
Tylosin use | Swine | Weaners | Farm | Tylosin was administered in feed (body weight dose of 3–6 mg/kg/day) to treat proliferative enteropathy. Measurement of treated pigs was 3-5 weeks after withdrawl of tylosin. | 7 |